Long-Term Control of Arterial Hypertension and Regression of Left Ventricular Hypertrophy With Treatment of Primary Aldosteronism
暂无分享,去创建一个
A. Pessina | G. Rossi | F. Mantero | C. Cuspidi | V. Bisogni | G. Maiolino | M. Cicala | M. Cesari
[1] R. Wachter,et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. , 2013, JAMA.
[2] R. Holle,et al. Observational Study Mortality in Treated Primary Aldosteronism: The German Conn's Registry , 2012, Hypertension.
[3] M. Allessie,et al. Aldosterone promotes atrial fibrillation. , 2012, European heart journal.
[4] J. McMurray,et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. , 2012, Journal of the American College of Cardiology.
[5] Mark E. Anderson,et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone , 2011, Nature Medicine.
[6] D. Farley,et al. Primary aldosteronism: results of adrenalectomy for nonsingle adenoma. , 2011, Journal of the American College of Surgeons.
[7] G. Rossi. A comprehensive review of the clinical aspects of primary aldosteronism , 2011, Nature Reviews Endocrinology.
[8] A. Morganti,et al. The aldosterone–renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma , 2010, Journal of hypertension.
[9] W. Young,et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. , 2008, The Journal of clinical endocrinology and metabolism.
[10] D. Rizzoni,et al. Inappropriate Left Ventricular Mass in Patients With Primary Aldosteronism , 2008, Hypertension.
[11] A. Parkhomenko,et al. History of Hypertension and Eplerenone in Patients With Acute Myocardial Infarction Complicated by Heart Failure , 2008, Hypertension.
[12] A. Triantafyllou,et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study , 2008, The Lancet.
[13] E. Porteri,et al. Vascular Remodeling and Duration of Hypertension Predict Outcome of Adrenalectomy in Primary Aldosteronism Patients , 2008, Hypertension.
[14] P. Strazzullo,et al. Primary aldosteronism: cardiovascular, renal and metabolic implications , 2008, Trends in Endocrinology & Metabolism.
[15] L. Sechi,et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. , 2008, Archives of internal medicine.
[16] L. Sechi,et al. Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients With Primary Aldosteronism , 2007, Hypertension.
[17] A. Dominiczak,et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. , 2007, Journal of hypertension.
[18] A. Dominiczak,et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.
[19] D. Rizzoni,et al. Inappropriate Left Ventricular Mass Changes During Treatment Adversely Affects Cardiovascular Prognosis in Hypertensive Patients , 2007, Hypertension.
[20] E. Porteri,et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. , 2006, Journal of the American College of Cardiology.
[21] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[22] P. Milliez,et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. , 2005, Journal of the American College of Cardiology.
[23] M. Mariani,et al. Excess ldosterone Is Associated With Alterations of Myocardial Texture in Primary Aldosteronism , 2002, Hypertension.
[24] R. Devereux,et al. Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension. , 2002, American journal of hypertension.
[25] F. Alla,et al. Treatment of Congestive Heart Failure: Interfering the Aldosterone-Cardiac Extracellular Matrix Relationship , 2001, Hypertension.
[26] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[27] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[28] T. Yoshimoto,et al. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. , 1997, Hypertension research : official journal of the Japanese Society of Hypertension.
[29] P. Palatini,et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. , 1997, Circulation.
[30] H. Okayama,et al. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. , 1997, Hypertension.
[31] H. Hense,et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. , 1997, Heart.
[32] D. Rizzoni,et al. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years of follow-up. , 1996, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[33] G. Reboldi,et al. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. , 1996, The American journal of cardiology.
[34] F. Yoshihara,et al. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension. , 1996, American journal of hypertension.
[35] P. Palatini,et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. , 1996, Hypertension.
[36] R. Lewanczuk,et al. Diagnosis and Treatment of Primary Aldosteronism , 1995, Annals of Internal Medicine.
[37] G. Reboldi,et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. , 1995, Journal of the American College of Cardiology.
[38] C. Delcayre,et al. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. , 1994, Hypertension.
[39] G. Chatellier,et al. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. , 1993, American journal of hypertension.
[40] K. Baker,et al. Cardiac Hypertrophy: Mechanical, Neural, and Endocrine Dependence , 1991 .
[41] M. Kuramochi,et al. Left ventricular structural characteristics in unilateral renovascular hypertension and primary aldosteronism. , 1988, American Journal of Cardiology.
[42] J. Laragh,et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. , 1986, Annals of internal medicine.
[43] N. Reichek,et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.
[44] M. Iida,et al. Role of aldosterone in left ventricular hypertrophy in hypertension. , 2006, American journal of hypertension.
[45] G. Rossi. Cardiac consequences of aldosterone excess in human hypertension. , 2006, American journal of hypertension.
[46] K. Weber,et al. Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation , 2004, The clinical investigator.
[47] 吉冨雄治. Comparison of changes in cardiac structure after treatment in secondary hypertension(二次性高血圧症における治療前後の左室構造の変化に関する比較検討) , 1998 .
[48] M. Roman,et al. Measurement of cardiac output by M-mode and two-dimensional echocardiography: application to patients with hypertension. , 1990, European heart journal.